Opiant Pharmaceuticals (NASDAQ:OPNT) released its earnings results on Tuesday. The technology company reported $1.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $1.87, Fidelity Earnings reports. The firm had revenue of $20.64 million for the quarter, compared to analyst estimates of $5.73 million. Opiant Pharmaceuticals had a negative return on equity of 12.74% and a negative net margin of 11.78%.
NASDAQ:OPNT traded down $0.35 during mid-day trading on Thursday, reaching $15.49. 2,204 shares of the stock were exchanged, compared to its average volume of 17,146. The business has a fifty day moving average price of $15.04 and a 200 day moving average price of $13.55. The firm has a market capitalization of $64.50 million, a PE ratio of -2.18 and a beta of 0.31. Opiant Pharmaceuticals has a 1-year low of $9.98 and a 1-year high of $18.23.
A number of research analysts recently issued reports on the company. Northland Securities reaffirmed a “buy” rating and set a $42.00 target price on shares of Opiant Pharmaceuticals in a report on Thursday, November 7th. TheStreet raised Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a report on Friday, August 30th.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Recommended Story: What is a death cross?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.